News Center

位置：

Honors Announcement

Group News

Media Reports

Shijiazhuang Sihua Pharmaceutical Group Honored as One of Hebei Province’s Top 100 Enterprises and Top 100 Manufacturers

Category:

Honors Announcement

发布时间：2025-04-10

【概要描述】 At today’s Conference on High-Quality Development of Large Enterprises in Hebei Province in the New Era and the 2024 Release Ceremony for the Top 100 Enterprises in Hebei, the Top 100 Manufacturing Enterprises in Hebei, the Top 100 Service Enterprises in Hebei, and the Top 50 Innovative Leaders, Shijiazhuang Sihua Pharmaceutical Group was recognized for its outstanding overall strength and innovative practices, earning a place on two prestigious rankings: No. 87 on the Top 100 Enterprises in Hebei and No. 54 on the Top 100 Manufacturing Enterprises in Hebei, thereby underscoring its leading position in the pharmaceutical manufacturing sector and the tangible results of its high-quality development.

Shijiazhuang Sihua Pharmaceutical Group Honored as One of Hebei Province’s Top 100 Enterprises and Top 100 Manufacturers

At today’s Conference on High-Quality Development of Large Enterprises in Hebei Province in the New Era and the 2024 Release Ceremony for the Top 100 Enterprises in Hebei, the Top 100 Manufacturing Enterprises in Hebei, the Top 100 Service Enterprises in Hebei, and the Top 50 Innovative Leaders, Shijiazhuang Sihua Pharmaceutical Group was successfully listed on two major rankings thanks to its outstanding overall strength and innovative practices, ranking as follows: No. ___ on the Hebei Top 100 Enterprises List 87th, No. ___ on the Top 100 List of Manufacturing Enterprises in Hebei Province Ranking 54th underscores its leading position in the pharmaceutical manufacturing sector and the effectiveness of its high-quality development.

As one of the leading enterprises in Hebei Province’s pharmaceutical industry, Shijiazhuang Sihua Pharmaceutical Group has consistently placed innovation-driven development at the forefront, regarding technological innovation as its core competitive advantage. In recent years, the Group has focused its R&D efforts on “innovative drugs, first-generic drugs, and specialty drugs,” continuously increasing its R&D investment and concentrating on key therapeutic areas such as anti-infectives, respiratory diseases, neurological disorders, cardiovascular and cerebrovascular conditions, gastroenterology, anesthesia, dialysis, endocrinology, and oncology. This strategy has enabled the Group to build a diversified R&D pipeline spanning both chemical drugs and active pharmaceutical ingredients, with several Class I new drugs now entering clinical trials. As a result, its research achievements have accumulated steadily and are now being translated into tangible outcomes, accelerating the release of innovative momentum and driving a remarkable transformation in its product portfolio—shifting toward high-end injectable formulations, greater formulation diversity, and specialized APIs. In 2024, the Group secured approval for 82 new products, placing it among the industry leaders in both the number of approvals obtained and applications submitted. So far this year, it has consecutively received approval for 20 new products, bringing the total number of approved or pending review varieties to 122, encompassing 164 dosage forms, thereby providing strong impetus for the company’s accelerated growth.

“Being named among the province’s Top 100 Enterprises and Top 100 Innovative Enterprises is a powerful affirmation of our commitment to achieving technological self-reliance and strength,” said the group’s head. The company has fostered deep integration among industry, academia, research institutions, and end-users, leveraging collaborative innovation partnerships with top-tier universities and research institutes to accelerate the efficient commercialization of scientific and technological advances and inject new momentum into the high-quality development of the industry.

Amid the wave of transformation and upgrading in the manufacturing sector, the Group is reshaping its production model through intelligent and green practices. In recent years, Shijiazhuang Sihua Pharmaceutical has leveraged digital transformation to build a state-of-the-art, vertically integrated smart infusion production workshop, introducing automated production lines and digital management systems. These initiatives have continuously enhanced production efficiency, expanded capacity, and improved product quality, accelerating the Group’s move toward smarter, higher-end manufacturing. At the same time, the Group has actively aligned with the “dual carbon” strategy by implementing systematic measures such as process optimization, the widespread adoption of energy-efficient equipment, and clean production. As a result, its bulk active pharmaceutical ingredient—caffeine—has successfully obtained carbon footprint certification, providing a green passport for market access in international markets. Currently, the product is exported to more than 60 countries and regions worldwide.

Shijiazhuang Sihua Pharmaceutical Group has been honored with the “Double Top 100” designation, marking a new breakthrough in the company’s transformation toward high-end, intelligent, and green operations. In the face of emerging opportunities in the biopharmaceutical industry, the group’s leadership stated that it will steadfastly pursue the goal of cultivating new-quality productive forces, accelerate the development of an industrial layout led by innovative drugs, supported by specialty generic drugs and active pharmaceutical ingredients, and synergized by pharmaceutical packaging materials and bioproducts, and strive to play an even greater role in advancing the high-quality development of Hebei’s biopharmaceutical sector.

According to available information, this selection process is jointly conducted by the Financial Office of the Hebei Provincial Party Committee, the Hebei Provincial Development and Reform Commission, the Hebei Provincial State-owned Assets Supervision and Administration Commission, the Hebei Provincial Department of Human Resources and Social Security, the Hebei Provincial Department of Commerce, the Hebei Provincial Department of Transport, the Hebei Provincial Department of Culture and Tourism, the Hebei Provincial Department of Science and Technology, the Hebei Provincial Administration for Market Regulation, the Hebei Provincial Department of Industry and Information Technology, and the Hebei Provincial Federation of Enterprises.

Keywords:

Felodipine API Approved by Shijiazhuang Sihua Pharmaceutical Group

Two New Standard-Format Products of Sodium Cytidine Diphosphate Choline Injection from Shijiazhuang Sihua Pharmaceutical Group Have Been Approved Simultaneously

Felodipine API Approved by Shijiazhuang Sihua Pharmaceutical Group

Two New Standard-Format Products of Sodium Cytidine Diphosphate Choline Injection from Shijiazhuang Sihua Pharmaceutical Group Have Been Approved Simultaneously